Trials / Completed
CompletedNCT05216224
ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ATI-450 vs Placebo in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 2a study to investigate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of ATI-450 vs placebo in patients with moderate to severe Hidradenitis Suppurativa (HS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATI-450 | Oral, small molecule MK2 inhibitor |
| DRUG | Placebo oral tablet | Placebo tablet manufactured to match ATI-450 in appearance |
Timeline
- Start date
- 2021-12-29
- Primary completion
- 2022-12-23
- Completion
- 2023-01-24
- First posted
- 2022-01-31
- Last updated
- 2026-01-07
- Results posted
- 2026-01-07
Locations
20 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05216224. Inclusion in this directory is not an endorsement.